Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar

- PMLiVE

AbbVie’s Humira wins ninth US approval

FDA approves multi-blockbuster for inflammatory skin disease

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

First Merck/Samsung biosimilar cleared in South Korea

Approval of Brenzys further opens up competition in biosimilar market

- PMLiVE

Novartis launches first biosimilar Zarxio in the US

Follows Amgen's failure to block Neupogen-version from release

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

- PMLiVE

NICE recommends infliximab biosimilars ahead of Remicade

Newly-acquired Hospira and Napp see their infliximab products backed by the HTA body

- PMLiVE

Genzyme and Ablynx collaborate on multiple sclerosis research

Companies will investigate Nanobodies against MS target

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links